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Abstract
Background: An increased risk of cardiovascular (CV) complications has been described in patients with
rheumatoid arthritis (RA). It is the result of the combined effect of classic CV risk factors and others that are specific
to the disease.
Methods: We assessed data from 448 early arthritis (EA) patients: 79% women, age (median [p25-p75]) at onset: 55
[44–67] years and disease duration at study entry 5 [3–8] months; and 72% fulfilled the 1987 RA criteria at 2 years of
follow-up. Rheumatoid factor was positive in 54% of patients and anti-citrullinated peptide antibodies in 50%. The
follow-up of patients ranged from 2 to 5 years with more than 1400 visits with lipoprotein measurements available
(mean 2.5 visits/patient). Demographic- and disease-related variables were systematically recorded. Total cholesterol
(TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) levels were obtained from routine
laboratory tests. Oxidized-LDL (oxLDL-C) levels were assessed using a commercial ELISA kit. We fitted population-
averaged models nested by patient and visit to determine the effect of independent variables on serum levels of
TC, its fractions, and oxLDL-C.
Results: After adjustment for several confounders, high-disease activity was significantly associated with decreased
TC, HDL-C, and LDL-C levels and increased oxLDL-C levels. Standardized coefficients showed that the effect of
disease activity was greater on oxLDL-C and HDL-C. Interestingly, we observed that those patients with lower levels
of LDL-C showed higher oxLDL-C/LDL-C ratios.
Conclusions: High-disease activity in EA patients results in changes in the HDL-C and oxLDL-C levels, which in turn
may contribute to the increased risk of CV disease observed in these patients.
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Background
There is a great body of evidence supporting that pa-
tients with rheumatoid arthritis (RA) display a higher
risk of cardiovascular events (CVE) than the general
population [1–5]. In addition, several studies have shown
that scores for predicting cardiovascular (CV) risk in the
general population based on traditional CV risk factors
(smoking, hypertension, obesity, diabetes, and dyslipid-
emia) underestimate the CV risk in patients with RA [6–
10]. This additional risk for CVE has been studied in
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terms of specific genetic background [3, 11] and in rela-
tion with the effect of disease activity on lipid profile in
these patients [12–19].
There is an increased CV risk in the general popula-
tion associated with an increase in total cholesterol
(TC), mainly low-density lipoprotein cholesterol (LDL-
C), and a decrease in high-density lipoprotein cholesterol
(HDL-C) levels, and, as a consequence, an increase in
the atherogenic index [20]. However, in patients with ac-
tive RA and other inflammatory disorders a “paradoxical
phenomenon” occurs with a decrease in TC and LDL-C
associated with an increase in CV risk [5, 21, 22]. Fur-
thermore, recently, it has been observed that those pa-
tients with very low LDL-C show a stronger association
with subclinical coronary atherosclerosis, similar to that
of patients with the highest levels of LDL-C, which has
been termed “the lipid paradox theory” [23]. The rela-
tionship between changes in the lipid metabolism and
RA disease activity has been analyzed in previous studies
with controversial results [12–19]. Several concerns re-
lated with previous studies may explain these controver-
sial results. Lipid profile in RA has been studied both in
observational cross-sectional studies of long-standing
RA and in randomized clinical trials in patients with
early arthritis (EA). Moreover, many of these studies in-
cluded a low number of patients and different outcomes
were measured in each work [12–19, 24–26].
An issue of potential interest regarding lipid profile
disturbances that appear over time in patients with RA
is whether these alterations are observed at the early
stages of the disease. To address this question, we ana-
lyzed how disease activity affects the lipid profile in a
population of patients with early arthritis without any
treatment at the baseline visit, who were followed-up for
up to 5 years in five protocolized visits.
Patients and methods
Design and patients
Retrospective analysis of data collected in the PEARL
(Princesa Early Arthritis Register Longitudinal) study in
order to determine the effect of disease activity on the
lipid profile of patients with early arthritis.
PEARL study includes incident cases of patients with
one or more swollen joints for less than a year referred
to our EA Clinic. Patients with gout, septic or viral arth-
ritis, osteoarthritis, spondyloarthritis, or connective tis-
sue diseases diagnosed during the follow-up period were
excluded from this analysis. Only those patients fulfilling
the 1987 ACR criteria for RA classification [27] and
those considered undifferentiated arthritis (UA) [28]
after 24 months of follow-up were included in this study.
The register includes 5 structured visits (baseline, 6, 12,
24, and 60 months) in which socio-demographic, clinical,
laboratory, therapeutic, and radiological data as well as
biological samples are systematically collected in parallel
with routine analysis after, at least, 10 h of fasting.
It is important to point out that there is no pre-
established therapeutic protocol in the PEARL study, so
the decision on when and how to treat the patients dur-
ing the follow-up relies on the responsible physicians
from the rheumatology department (see Supplementary
Table 1 for the description of treatments along with the
follow-up). Nevertheless, the register specific evaluation
visits are performed by only two rheumatologists (AMO,
IG-A) in an attempt to achieve more accurate clinical
evaluation, especially regarding joint counts. A more de-
tailed description of the PEARL study has been previ-
ously published [29]. The register started in 2000 and it
is still ongoing. However, for this analysis, we only used
the visits included in the database until June 2018.
Disease activity stratification was performed applying
cut-offs previously described: DAS28 estimated using ei-
ther erythrocyte sedimentation rate (ESR) [30] or C-
reactive protein (CRP) [31], Simplified Disease Activity
Index (SDAI) and Clinical Disease Activity Index (CDAI)
[32], and Hospital Universitario Princesa Index (HUPI)
[33]. Disability was assessed with the Spanish version of
the Health Assessment Questionnaire (HAQ) [34].
Lipid profile measurements
TC levels, HDL-C, LDL-C, very low-density lipoproteins
(VLDL-C) fractions, and triglycerides (TG) levels were
estimated in routine blood tests at the local biochemistry
laboratory of our center. TC, HDL-C, and TG concen-
trations were determined through the enzymatic method
in a Hitachi 911 analyzer (CHOP-PAP, GPO-PAP, and
HDL-direct, respectively; Roche Diagnostics). LDL-C
was estimated through the Friedewald formula [35, 36]:
LDL = TC−HDL–0.2 × TG.
Although it was established per protocol to measure
the total lipid profile in all visits, due to the fact that
some patients missed some visits or to the occasional
decision of the biochemistry laboratory to skip measur-
ing cholesterol fractions when TC was below 200mg/dl,
there were missing data for some of the variables. There-
fore, the data from blood tests available for analyses
were TC from 1416 visits, HDL-C from 977 visits, LDL-
C from 929 visits, VLDL-C from 717 visits, and TG from
848 visits.
Oxidized-LDL evaluation
Since our center does not routinely measure oxidized-
LDL-C (oxLDL-C) levels, we determined them in frozen
serum samples from our register through a commercial
ELISA kit (Mercodia AB, Uppsala, Sweden) following
the manufacturer’s instructions for use. To evaluate the
effect of frozen storage time on oxLDL-C measurements,
we analyzed a subpopulation of 104 samples with a
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range of storage from 6 to 40months evenly distributed
throughout our register. As it is shown in Supplemen-
tary Figure 1, for periods of frozen storage longer than
12months, the capability to measure oxLDL-C levels
was severely impaired. Therefore, we decided to perform
the current study exclusively with samples that were fro-
zen for less than 12months. This approach allowed us
to obtain data about oxLDL-C serum levels from 270
visits from a subpopulation of 167 patients (1.5 visits per
patient). The intra- and inter-assay variability were cal-
culated by repeating four samples (two with high value
and two with a low value) in six wells of four independ-
ent ELISA plates. According to our measurements,
intra-assay and inter-assay variability coefficients were
9.5% and 22.3%, respectively.
Statistical analysis
Normally distributed quantitative variables were repre-
sented as the mean (± standard deviation: SD), while
non-normally distributed variables were represented as
the median and interquartile range (IQR). Qualitative
variables were described using a calculation of the pro-
portions. Variables with a normal distribution were ana-
lyzed by the t test or ANOVA, while the Mann-Whitney
or Kruskal-Wallis tests were used for variables with a
non-normal distribution. A χ2 or Fisher’s exact test was
used to compare categorical variables.
After bivariate analysis to identify independent factors
that influenced TC, HDL-C, LDL-C, oxLDL-C, VLDL-C,
and TG levels during the follow-up, we fitted six
population-averaged models by generalized linear
models nested by the patient and visit using the xtgee
command of Stata 12.1 for Windows (StataCorp LP,
College Station, Texas, USA). Since oxLDL-C values did
not follow a Gaussian distribution, this variable was nor-
malized by calculating the square root of its values. In
this case, the sqrt_oxLDL-C variable was used as a
dependent variable. The remaining models were fitted
with the raw data since TC, HDL-C, LDL-C, VLDL-C,
and TG levels approximately followed Gaussian distribu-
tions. The population-averaged generalized estimating
equations were first modeled by adding all variables with
a p value < 0.15 in the bivariate analysis. The final
models were constructed using quasi-likelihood estima-
tion based on the independence model information cri-
terion [37] and Wald tests, removing all variables with
p > 0.15. The variable time of frozen storage was always
included in the multivariate analysis of oxLDL-C levels.
Since six different multivariate analyses were fitted, to
adjust for multiple comparisons, we applied Bonferroni
correction and the statistical significance was set at <
0.01.
We performed sensitivity analyses for all dependent
variables repeating the statistical models only with the
visits in which patients were not taking statins. These
sensitivity analyses yielded no relevant differences with
the models that included the whole population (Supple-
mentary Table 2).
In addition, to compare which variables had a propor-
tionally higher influence on the lipoprotein profile, we
estimated standardized coefficients by repeating the
multivariate analysis with new standardized variables
generated with the egen command of Stata with the op-
tion std, which produces variables with mean 0 and
standard deviation 1.
To determine which component of disease activity in-
dexes was responsible for most of the effect on lipids, in
the models with standardized variables, we replace the
variable disease activity by the individual standardized
components, namely CRP, swollen and tender joint
counts, and global disease assessment by the patient.
Results
Description of the population
The baseline characteristics of patients are shown in
Table 1. Briefly, the study sample comprised 448 pa-
tients; 79% of them were women and 324 (72%) fulfilled
1987 ACR criteria for RA classification, while 124 (28%)
were classified as UA. The median age at baseline was
55 years (interquartile range [IQR] 44–67) and the me-
dian disease duration 5 months (IQR: 3–8). Baseline dis-
ease activity on average was moderate with all the 5
indexes used in the study.
The HAQ showed mild/moderate disability. Almost
half of the population suffered from the seropositive dis-
ease [(rheumatoid factor (RF) or anti-citrullinated pep-
tide antibodies (ACPA)], and 21% were active smokers
and the average body mass index (BMI) of patients indi-
cated a slight overweight. Less than 11% of patients were
using statins at baseline and information on the use of
these drugs was collected at each visit.
Differences between patients with or without oxLDL-C
measurement
As shown in Table 1, oxLDL-C was assessed in 167 of
the 448 patients. This subgroup of patients had longer
disease duration at baseline and a non-significantly in-
creased disease severity. However, other features were
similar in both groups. (Table 1). Therefore, patients in
which oxLDL-C was analyzed constituted a representa-
tive cohort of Spanish individuals with EA. In this re-
gard, Supplementary Table 1 shows that patients were
mainly treated with methotrexate, antimalarials, and
leflunomide without significant differences between both
groups. In addition, a non-significant trend to higher
percentages of patients treated with tocilizumab, abata-
cept, or rituximab was observed in patient in which
oxLDL-C measurement was not carried out.
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Table 1 Baseline characteristics of patients included in the PEARL study
Total population (N = 448) oxLDL not studied (N = 281) oxLDL studied (N = 167) p
Female gender (%) 354 (79) 224 (79.7) 130 (77.8) 0.638
Age (years) 55 [44–67] 58 [44–68] 52 [43–65] 0.08
Disease duration (months) 5 [3–8] 5 [3–8] 6 [4–9] 0.004
DAS28 4.4 [3.3–5.5] 4.1 [3.3–5.5] 4.7 [3.5–5.7] 0.060
SDAI 18 [9.6–29.2] 17 [8.8–29] 19.2 [10.4–29.5] 0.183
HUPI 7 [4.5–10] 7 [4–10] 8 [5–9.5] 0.174
HAQ 0.875 0.875 1 0.059
[0.5–1.625] [0.375–1.625] [0.625–1.625]
RF (%) 54 57 48 0.054
ACPA (%) 50 53 46 0.175
UA (%) 28 26 30 0.297
Smoking (%) 21.4 20 24.2 0.36
Statins use (%) 10.7 12 9 0.361
BMI p50 [IQR] 26.1 [23.4–29] 25.9 [22.9–29] 26.3 [23.9–29.1] 0.171
Significance was considered if p < 0.05. In bold significant p values
Abbreviations: ACPA anti-citrullinated protein antibodies, BMI body mass index, DAS28 Disease Activity Score (28 joints count), HAQ Health Assessment
Questionnaire, HUPI Hospital Universitario La Princesa Index, IQR interquartile range, N number, oxLDL oxidized LDL cholesterol, p p value, PEARL Princesa Early
Arthritis Register Longitudinal, RF rheumatoid factor, SDAI Simplified Disease Activity Index, UA undifferentiated arthritis
Table 2 Variables that have an influence on lipid profile of patients with early arthritis
Total cholesterol (mg/dl) HDL cholesterol (mg/dl) LDL cholesterol (mg/dl) oxLDL (sqrt U/ml)
β coeff. ± s.e. p β coeff. ± s.e. p β coeff. ± s.e. p β coeff. ± s.e. p
Gender
Male Ref. – Ref. – n.i. – Ref. –
Female 10.5 ± 3.4 0.002 12.4 ± 1.9 < 0.001 −1.03 ± 0.48 0.031
Age
< 45 years Ref. – Ref. – Ref. – n.i.
45–65 years 23.1 ± 3.3 < 0.001 1.9 ± 1.9 0.319 16.4 ± 3.3 < 0.001
> 65 years 23.9 ± 3.7 < 0.001 5.6 ± 2.1 0.008 12.3 ± 3.7 0.001
BMI 0.68 ± 0.29 0.019 −0.62 ± 0.16 < 0.001 0.71 ± 0.29 0.016 n.i.
DA
Remission Ref. – Ref. – Ref. – Ref. –
Low 2.19 ± 1.74 0.582 −0.79 ± 1.04 0.442 1.96 ± 2.13 0.359 0.28 ± 0.48 0.564
Moderate −3.04 ± 1.90 0.110 −3.30 ± 1.14 0.004 1.35 ± 2.30 0.556 0.43 ± 0.48 0.367
High −14.95 ± 2.53 < 0.001 −8.89 ± 1.56 < 0.001 −6.39 ± 2.92 0.029 1.88 ± 0.66 0.004
Statins −27.4 ± 3.05 < 0.001 n.i. − 28.7 ± 3.2 < 0.001 n.i.
Smoking n.i. n.i. 7.0 ± 4.5 0.118 n.i.
MTX (mg/wk) n.i. 2.06 ± 0.94 0.029 n.i. n.i.
Leflunomide (mg/d) 6.4 ± 2.2 0.003 2.35 ± 1.27 0.064 4.79 ± 2.57 0.062 n.i.
Abatacept (Y/N) 36.94 ± 16.01 0.021 40.54 ± 9.57 < 0.001 n.i. n.i.
TNF i (Y/N) n.i. n.i. n.i. 1.597 ± 1.003 0.111
LDL (mg/dl) n.i. n.i. n.i. 0.015 ± 0.005 0.005
Frozen storage (months) n.i. n.i. n.i. −0.003 ± 0.001 < 0.001
Abbreviations: β coeff. beta coefficient, BMI body mass index, DA Disease activity assessed with, HUPI Hospital Universitario La Princesa Index, HDL high-density
lipoproteins, LDL low-density lipoproteins, MTX methotrexate, N no, n.i. not included (not relevant to the model), oxLDL oxidized LDL, p p value, Ref. reference
variable, s.e. standard error, sqrt square root, n.i. not included (not relevant to the model), TNFi TNF inhibitors, wk week, Y yes. Due to multiple comparisons,
statistical significance was considered if p < 0.01. In bold, significant p values
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Variables associated with TC levels throughout the
follow-up of early arthritis patients
As shown in Table 2, TC was significantly higher in fe-
male and patients older than 45 years, as well as in those
visits in which patients were being treated with lefluno-
mide. In addition, a non-significant trend to higher levels
of TC was observed with increasing BMI, as well as in
visits in which the patients were being treated with aba-
tacept (Table 2). As expected, TC was significantly lower
in those visits in which patients were being treated with
statins (Table 2).
After adjustment for these confounders, we observed
that only high-disease activity according to HUPI assess-
ment was significantly associated with lower levels of TC
(Table 2).
The most relevant variable affecting TC was age,
followed by statins (Fig. 1a). Disease activity had an ef-
fect similar to those of gender and BMI (Fig. 1a).
Similar findings were observed when disease activity
was assessed with other indexes (Supplementary Ta-
bles 3, 4, 5, and 6).
Variables associated with HDL-C levels throughout the
follow-up
As described for TC, female patients showed a signifi-
cant increase of HDL-C levels compared to male pa-
tients (Table 2). Using individuals younger than 45 years
as a reference, a trend for high HDL-C levels was ob-
served in patients older than 65 years (Table 2). In con-
trast, HDL-C levels significantly decreased with
increasing values of BMI (Table 2). After adjustment for
these variables, the multivariate analysis showed that in-
creasing levels of disease activity induced a dose-
dependent decrease of HDL-C, being statistically signifi-
cant for moderate and high-disease activity (Table 2).
Treatment with methotrexate, leflunomide, and abata-
cept was also associated with an independent increase of
HDL-C levels, which was only statistically significant for
abatacept (Table 2).
Regarding the magnitude of the effect on HDL-C
levels, disease activity showed an effect size similar to
BMI, age, and gender, whereas the relative effect of
treatments seemed to be lower (Fig. 1b). Additional in-
formation about data related to disease activity assessed
with other indexes is shown in Supplementary Tables 3,
4, 5, and 6.
Variables associated with LDL-C levels throughout the
follow-up
As expected, LDL-C levels were significantly lower in
those visits in which the patients were being treated with
statins (Table 2). In contrast, LDL-C levels were signifi-
cantly higher in patients older than 45 years and in-
creased in parallel with increasing BMI (Table 2).
High-disease activity was significantly associated with
lower LDL-C levels (Table 2), although compared to
other variables that significantly affected LDL-C levels,
the effect of disease activity was clearly mild (Fig. 1c).
Similar findings were observed when disease activity was
assessed with other activity indexes (Supplementary Ta-
bles 3, 4, 5, and 6).
Variables associated with oxidized LDL-C levels
As mentioned in the “Patients and methods” section, the
frozen time of serum samples significantly decreased the
capability to detect oxLDL-C (Table 2 and Supplemen-
tary Figure 1). In addition, oxLDL-C levels were directly
associated with total LDL-C levels (Table 2). Women
showed slightly lower oxLDL levels than men, although
no statistical significance was reached (Table 2).
After adjustment for these relevant variables, the
multivariate analysis showed a significant increase of
oxLDL-C levels when disease activity was high (Table 2).
This effect was similar to that of LDL-C levels (Fig. 1d).
Additional information about data related to disease
activity assessed with other indexes is shown in Supple-
mentary Tables 3, 4, 5, and 6.
On the other hand, it has been recently described that
patients with low-circulating LDL-C or very high-LDL-C
show a stronger association with subclinical coronary
atherosclerosis than patients with normal LDL-C [23].
We were interested in knowing whether this lipid para-
dox in RA patients could be explained by LDL-C oxida-
tion. Figure 2 shows that the proportion of oxidized
LDL-C (oxLDL-C/LDL-C ratio) was significantly higher
in visits in which patients showed high-disease activity.
Despite this observation, a clear correlation between
oxLDL-C and LDL-C levels was only observed in visits
in which patients showed low-disease activity (Fig. 3
upper right panel). Interestingly, in visits in which pa-
tients had moderate or high-disease activity, patients
with low LDL-C showed similar levels of oxLDL-C than
those with higher LDL-C (Fig. 3 lower panels). Further-
more, the proportion of oxLDL-C was significantly
higher in patients with the lowest level of total LDL-C
(Fig. 4).
Variables associated with VLDL-C and TG levels
The main variable associated with these lipid fractions
was BMI. Neither relevant nor significant effect of dis-
ease activity was observed in the serum levels of these
two parameters (Fig. 1e and f; Supplementary Tables 7
and 8).
Standardized effect of disease activity on lipid profile
Finally, comparing standardized coefficients, Fig. 5
shows that disease activity induced a dose-dependent ef-
fect on HDL-C (decreasing its levels) and oxLDL-C
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(increasing its levels). However, a mild effect on total
LDL-C was observed; therefore, the decrease in TC
when patients are active mainly relies on the HDL-C
fraction (Fig. 5).
On the other hand, we were interested in which com-
ponent of the composite indexes had a greater influence
on the changes in lipids. CRP, followed by the swollen
joint count, had the highest effect on lipids, especially on
LDL-C, being the effect of tender joints and global
disease assessment by the patient which is the lowest
(Supplementary Figure 2).
Discussion
The findings described in this study suggest that high-
disease activity in patients with EA induces a transform-
ation of their lipid profile into a pro-atherogenic one by
Fig. 1 Effect of different variables on the lipid profile of patients with early arthritis. a Total cholesterol. b HDL cholesterol. c LDL cholesterol. d
Oxidized LDL cholesterol. e VLDL cholesterol. f Triglycerides. Data are shown as the respective standardized coefficients (black dot) and their 95%
confidence interval (black bar) estimated with the multivariate analysis described in the “Patients and methods” section
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inducing a decrease in HDL-C levels and promoting
LDL oxidation. In addition, the longitudinal design of
our study and the availability of many variables that may
affect cholesterol levels have allowed us to determine
that the effect of disease activity on the levels of LDL-C
fraction is limited and probably not so relevant. Interest-
ingly, our data show that those patients with low LDL-C
suffer a proportionally higher oxidation of this molecule,
a finding that may explain the lipid paradox theory.
With regard to the effect of disease activity on lower-
ing HDL-C levels, our data are in accordance with infor-
mation reported previously [38–40]. Disease activity had
a similar effect to other variables, such as gender and
BMI, reported to affect HDL-C levels in the general
population. However, disease activity has an additional
effect on HDL-C since different studies suggest that an
inflammatory state not only decreases the levels of
HDL-C but also has an influence in its atheroprotective
Fig. 2 Effect of disease activity on the ratio of oxidized LDL cholesterol to total LDL cholesterol of patients with early arthritis. Data are
represented as box plots including median (line inside the boxes) and the percentiles 25, 75 (lower and upper lines of the boxes), and 10 and 90
(endpoints of the lines outside the boxes). Dots represent outliers. The level of disease activity was established with HUPI as previously described
[33]. Statistical significance was established with the Mann-Whitney test. Due to multiple comparisons, the significance level was set to 0.008
Fig. 3 Correlation between oxidized LDL cholesterol and total LDL cholesterol according to the level of disease activity in patients with early
arthritis. Data are shown as dot plots of the values in the visits in which the patients were in remission (upper left panel), low (upper right panel),
moderate (lower left panel), or high-disease activity (DA) established with HUPI as previously described [33]. Black lines represent the respective
linear regressions estimated through the twoway lfit command of Stata 12.1. R and p values were obtained with the Pearson’s test
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capacity [39, 41, 42]. Therefore, the usual HDL functions
are abolished transforming HDL-C into a pro-
atherogenic factor [43, 44]. Regarding the mechanisms
underlying these changes in the HDL-C fraction, it has
been proposed that myeloperoxidase (MPO) released by
phagocytes during the inflammatory process can induce
the production of substances driving changes in the
HDL-C fraction, especially oxidation of lipids and apo-
protein A1 (apoA1) [45].
Our data also shed light into the paradoxical finding of
low LDL-C levels in RA together with a high prevalence
of CV disease associated with this disorder. Our
Fig. 4 Ratio of oxidized LDL cholesterol to LDL cholesterol in patients with early arthritis classified in different strata according to their LDL cholesterol
level. Data are represented as box plots including median (line inside the boxes) and the percentiles 25, 75 (lower and upper lines of the boxes), and
10 and 90 (endpoints of the lines outside the boxes). Dots represent outliers. Strata of LDL cholesterol levels were defined as described by Giles et al.
[23]. Statistical significance was established using Cuzick’s non-parametric trend test, and the significance level was set to 0.05
Fig. 5 Comparative effect of disease activity on the lipid profile of patients with early arthritis. Data are shown as the standardized coefficients of
low-disease activity (DA; white bar), moderate DA (gray bar), and high-disease activity (black bar) from the multivariate analysis described in the
“Patients and methods” section. Remission was the reference category of the disease activity variable
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multivariate analysis let us unravel that disease activity
has an effect on total LDL-C levels in patients with EA.
Among the different components included in disease ac-
tivity indexes, CRP displayed the highest effect in lower-
ing TC and LDL-C. Thus, our results point to IL-6 as a
responsible for this finding, since it has been described
that this cytokine increases the LDL receptor on hepato-
cytes and LDL-C catabolism, that improve after blockade
of IL-6 signaling [46–48]. However, the inflammatory
status, especially in patients with high-disease activity,
has the most potent association with LDL oxidation
compared to its effect in other lipid fractions. This ob-
servation is in accordance with previous reports [49]. In
addition, the patients with lower levels of LDL-C were
those with proportionally higher levels of oxLDL-C,
which could explain why these patients show higher
levels of atherosclerosis [23]. Furthermore, it has been
described as an increase in anti-oxLDL antibody levels
when RA patients are active which improves after con-
trolling the disease activity, suggesting that oxLDL-C
may act as an autoantigen [50].
Regarding the mechanisms underlying LDL oxidation,
it is likely that two mechanisms may contribute: as de-
scribed for HDL oxidation, the degranulation of phago-
cytes increases the level of oxygen radicals and of MPO
activity, along with a reduction of Paraoxonase 1
(PON1) enzymatic function in HDL-C [43, 51]. PON1,
an HDL-associated hydrolytic enzyme with a wide range
of substrates, is responsible for most of the antioxidant
properties of HDL and has a high capability of protect-
ing against lipid oxidation in inflammation as well as in
normal physiologic situations [52–54]. In addition,
PON1 has a protective role in coronary artery disease
and ischemic stroke [55]. Since several studies indicate
that PON1 activity is reduced in inflammatory chronic
diseases such as RA [56, 57], it is likely that a decrease
in PON1 function can explain the atherogenic lipid pro-
file observed when our patients display a high-disease
activity and therefore the increased risk for CVE [58].
The longitudinal design of our study allowed us to
clarify whether the effect of different drugs on lipid
levels is related to the improvement of disease activity or
there is a specific effect of these drugs. This question
was raised for different drugs in several clinical trials
[39, 59, 60]. Our data suggest that methotrexate, abata-
cept, and probably leflunomide may exert a beneficial
effect upon HDL-C levels that would be independent of
the improvement of disease activity, although the size of
the effect of these treatments seems to be low.
Our study has some limitations. First, the serum lipid
profile of patients included in this study was not avail-
able in all the visits of all patients. This is a common
drawback in observational retrospective studies, but we
think that it could be compensated by the high number
of patients and visits carried out, which allowed us to
implement longitudinal multivariate analysis nested by
the patient and visit with more than 950 visits for the
different fractions and more than 1400 visits for TC.
The only exception was oxLDL-C analysis, which in-
cluded 259 visits in 157 patients. This was the conse-
quence of the second limitation of our study, measuring
oxLDL-C levels in frozen serum samples. Most kits for
measurement of oxLDL, including that from Mercodia®
used in this study, recommend using fresh serum sam-
ples. However, due to the retrospective nature of our
study, we had to use frozen serum samples limiting the
number of samples as it was described in the “Patients
and methods” section and requiring adjusting the ana-
lysis for the time of frozen storage. Nevertheless, despite
this limitation, we think that the analysis of oxLDL-C in
our study provides interesting information.
Another potential limitation refers to the analysis of
the effect of biologic therapies on the lipid profile. Since
we studied mainly the first 5 years of follow-up of pa-
tients with EA, few visits included treatment with such
drugs. The best represented was the TNF inhibitors
group (Supplementary Table 1), but the information
provided in this study on the effect of abatacept on
HDL-C levels relies on information from few visits and
it has to be confirmed in a specific study. However, it fits
well with a recent study suggesting that abatacept
reduces CV risk by 20% more than TNF inhibitors [61].
Conclusions
Overall, our data suggest that mainly patients that re-
main with moderate and high-disease activity suffer an
additional risk of CV disease due to RA, since only these
patients show relevant changes in the levels of HDL-C
fraction and oxLDL-C. In addition, the changes in
oxLDL-C are especially relevant in patients with low
LDL-C. These findings are in keeping with descriptions
showing a decreased incidence of CV disease in patients
treated either with methotrexate or biologic agents [62–
64], since an increasing number of patients reach low-
disease activity and remission at present [65]. Moreover,
our findings can also explain why a beneficial effect pre-
venting cardiovascular events has not been observed
with methotrexate in the general population [66] or with
atorvastatin in non-selected RA patients [67].
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Additional file 1: Supplementary Figure 1. Effect of time of frozen
serum storage on the measurement of oxidized low density lipoproteins
from patients with early arthritis. Data are shown as the individual values
of 104 serum samples with a range of frozen storage from 6 to 40
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months (black dots) and the linear regression (black line) estimated
through the twoway lfit command of Stata 12.1.
Additional file 2: Supplementary Figure 2. Comparative effect of the
different components of disease activity indexes on the total cholesterol
levels. A) Total cholesterol. B) LDL cholesterol. C) HDL cholesterol. Data
are shown as the standardized coefficients (black dots) and their
respective 95% confidence intervals (black lines) from the multivariate
analysis described in Methods in which the variable disease activity was
substituted by the different components included in the disease activity
indexes: global disease assessment by patient (GDA Pat), tender joint
count (TJC), swollen joint count (SJC) or C-reactive protein (CRP).
Additional file 3: Supplementary Table 1. Treatment prescribed to
PEARL patients along the follow-up. Supplementary Table 2. Sensitivity
analysis of variables that have influence on lipid profile only including pa-
tients that did not take statins. Supplementary Table 3. Variables that
have influence on lipid profile, including disease activity estimated by
CRP-DAS28. Supplementary Table 4. Variables that have influence on
lipid profile, including disease activity, estimated with ESR-DAS28. Sup-
plementary Table 5. Variables that have influence on lipid profile, in-
cluding disease activity, estimated with SDAI. Supplementary Table 6.
Variables that have influence on lipid profile, including disease activity, es-
timated with CDAI. Supplementary Table 7. Variables that have influ-
ence on VLDL Cholesterol levels. Supplementary Table 8. Variables that
have influence on triglyceride levels.
Additional file 4. Raw data used for this work (in Stata format).
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